-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Post-injection risk in adolescents was significantly increased after the second dose, and vaccination doses may need to be improved
A case-control study found an increased relative risk of carditis associated with BNT162b2 (Pfizer) vaccination despite a low absolute risk
Carditis is a rare inflammation of the heart, often caused by bacterial, viral, and parasitic infections
Researchers at the University of Hong Kong studied 160 case patients (with myocarditis) and 1533 control patients (without myocarditis) to examine potential heart disease risks associated with vaccination with BNT162b2
After conducting the analysis, the authors found 20 cases of myocarditis associated with BNT162b2 and 7 cases associated with CoronaVac
The authors also observed that the increased risk associated with BNT162b2 occurred primarily in men and was more likely to appear after the second dose
The cumulative incidence of post-vaccination cardiac inflammation was 0.
According to the authors' study, none of the 20 patients with carditis who received the BNT162b2 vaccine were admitted to the ICU or died during the observation period, compared to 14 of the 133 unvaccinated patients admitted to the ICU who died and 12 died during the observation period.
Reference: 24 January 2022, Annals of Internal Medicine .
